Gilead Sciences, Inc. (GILD) is Sphera Funds Management LTD.’s 6th Largest Position
Sphera Funds Management LTD. lifted its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 18.3% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 420,000 shares of the biopharmaceutical company’s stock after acquiring an additional 65,000 shares during the quarter. Gilead Sciences accounts for 3.7% of Sphera Funds Management LTD.’s holdings, making the stock its 6th biggest position. Sphera Funds Management LTD.’s holdings in Gilead Sciences were worth $32,428,000 as of its most recent SEC filing.
Other large investors have also added to or reduced their stakes in the company. Alps Advisors Inc. boosted its holdings in Gilead Sciences by 5.0% during the second quarter. Alps Advisors Inc. now owns 672,039 shares of the biopharmaceutical company’s stock worth $48,145,000 after buying an additional 32,101 shares in the last quarter. D.A. Davidson & CO. lifted its holdings in Gilead Sciences by 4.6% during the second quarter. D.A. Davidson & CO. now owns 87,469 shares of the biopharmaceutical company’s stock valued at $6,196,000 after purchasing an additional 3,863 shares in the last quarter. Davidson Investment Advisors lifted its holdings in Gilead Sciences by 11.7% during the second quarter. Davidson Investment Advisors now owns 316,994 shares of the biopharmaceutical company’s stock valued at $22,456,000 after purchasing an additional 33,159 shares in the last quarter. Bbva Compass Bancshares Inc. lifted its holdings in Gilead Sciences by 81.4% during the second quarter. Bbva Compass Bancshares Inc. now owns 33,739 shares of the biopharmaceutical company’s stock valued at $2,389,000 after purchasing an additional 15,143 shares in the last quarter. Finally, Landmark Bank purchased a new position in Gilead Sciences during the second quarter valued at $2,241,000. Hedge funds and other institutional investors own 78.19% of the company’s stock.
A number of research analysts recently issued reports on GILD shares. Mizuho reiterated a “buy” rating and issued a $94.00 price target on shares of Gilead Sciences in a research note on Friday, August 10th. BidaskClub downgraded shares of Gilead Sciences from a “hold” rating to a “sell” rating in a research report on Saturday, August 18th. ValuEngine downgraded shares of Gilead Sciences from a “hold” rating to a “sell” rating in a research report on Monday, August 20th. Piper Jaffray Companies set a $85.00 price objective on shares of Gilead Sciences and gave the stock a “buy” rating in a research report on Wednesday, September 12th. Finally, Zacks Investment Research downgraded shares of Gilead Sciences from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 25th. Eleven research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $88.63.
GILD traded down $1.20 during trading on Friday, hitting $68.99. The stock had a trading volume of 470,388 shares, compared to its average volume of 6,525,715. The company has a debt-to-equity ratio of 1.09, a quick ratio of 3.37 and a current ratio of 3.45. The stock has a market capitalization of $89.97 billion, a P/E ratio of 8.06, a P/E/G ratio of -2.70 and a beta of 1.01. Gilead Sciences, Inc. has a twelve month low of $64.27 and a twelve month high of $89.54.
Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, October 25th. The biopharmaceutical company reported $1.84 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.63 by $0.21. The company had revenue of $5.60 billion for the quarter, compared to analysts’ expectations of $5.44 billion. Gilead Sciences had a net margin of 7.12% and a return on equity of 39.32%. During the same period in the previous year, the company posted $2.27 EPS. Sell-side analysts predict that Gilead Sciences, Inc. will post 6.44 EPS for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 28th. Shareholders of record on Friday, December 14th will be paid a $0.57 dividend. The ex-dividend date of this dividend is Thursday, December 13th. This represents a $2.28 annualized dividend and a yield of 3.30%. Gilead Sciences’s dividend payout ratio is currently 26.64%.
Gilead Sciences Company Profile
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.
Featured Article: Are analyst ratings accurate?
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.